NCT02352974View on ClinicalTrials.gov

GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

GAD-Alum

DRUG

Vitamin D

Trial Locations (1)

Unknown

Linköping University, Linköping

Sponsors

Collaborators (1)

Diamyd Medical AB
All Listed Sponsors
collaborator

Swedish Child Diabetes Foundation

OTHER

collaborator

Ostergotland County Council, Sweden

OTHER

collaborator

Diamyd Medical AB

INDUSTRY

lead

Johnny Ludvigsson

OTHER_GOV

NCT02352974 - GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1) | Biotech Hunter | Biotech Hunter